The stock may trade on sentiment around the December 2026 readout. Monitor for any safety signals or early efficacy hints from the investigator. Given tiny market cap ($9M), positive data could drive significant upside, but failure risk is high.
Price Chart
Executive Summary
AIM ImmunoTech announced completion of enrollment in the Phase 2 DURIPANC study combining Ampligen with Imfinzi for metastatic pancreatic cancer, with the primary endpoint evaluation on track for December 2026. The update also highlighted prior Named Patient Program data showing 19.7 months median survival vs 8.6 months standard of care. This interim progress report is mildly positive but lacks final efficacy data.
Key Facts
- Enrollment completed in Phase 2 DURIPANC study of Ampligen + Imfinzi for pancreatic cancer
- Primary endpoint (Clinical Benefit Rate at 6 months) evaluation planned for December 2026
- Prior NPP monotherapy data showed median overall survival of 19.7 months vs 8.6 months standard of care
- Company is planning a pivotal Phase 3 trial of Ampligen with a PD-1 inhibitor
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech. Positive clinical progress could support future fundraising or partnership value.
Risk Factors
- Clinical trial failure: primary endpoint may not be met
- Small sample size (up to 25 subjects) limits statistical power
- Long timeline to catalyst (December 2026) with no interim data expected
- History of volatile stock moves and poor prior call performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308124 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers